DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of presbyopia, historical and forecasted epidemiology as well as the presbyopia market trends in the United States, EU4, and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Presbyopia Market with DelveInsight’s In-Depth Report @ Presbyopia Market Size
Key Takeaways from the Presbyopia Market Report
- In the assessment done by DelveInsight, the estimated total prevalent cases of presbyopia in the 7MM were ~325 million in 2023.
- The highest total diagnosed prevalent cases of Presbyopia were accounted by the US in 2023 (~109 million), which is expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of presbyopia with ~32 million cases, followed by Italy, which had diagnosed prevalent population of ~24 million in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (~18 million cases).
- Japan had ~50 million total diagnosed prevalent cases of Presbyopia in 2023, accounting for approximately 18% in 7MM.
- In 2023, in the US, the gender-specific diagnosed prevalent cases of presbyopia were highest for females (~60%), as compared to males (~40%), which is attributed to factors such as hormonal differences, ocular anatomy and physiology, lifestyle and occupational factors and others.
- The age-specific instances of presbyopia in the 7MM were highest for the age group 60–69 (~78 million cases), followed by the age group of less than 60 years (~77 million cases), 70–79 years (~69 million cases), and the age group =80 years (~53 million) in 2023.
- In 2023, presbyopia cases were further sub-segmented based on severity into mild and moderate to severe. Among the 7MM, the highest diagnosed prevalence was observed in moderate to severe, with ~212 million cases, compared to ~56 million mild cases.
- The leading Presbyopia Companies such as AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire Pharma, and others.
- Promising Presbyopia Therapies such as Pilocarpine, Phentolamine Opthalmic Solution 0.75%, UNR844-Cl, CSF-1, and others.
Navigate the complexities of the Presbyopia Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Presbyopia Market Forecast. Click here to get more insights @ Presbyopia Treatment Market
Presbyopia Epidemiology Segmentation in the 7MM
- Total Presbyopia Prevalent Cases
- Total Presbyopia Diagnosed Prevalent Cases
- Presbyopia Age-specific Diagnosed Prevalent Cases
- Presbyopia Gender-specific Diagnosed Prevalent Cases
- Presbyopia Severity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Presbyopia epidemiology trends @ Presbyopia Prevalence
Presbyopia Marketed Drugs
- VUITY (pilocarpine HCI ophthalmic solution) 1.25%: Allergan/AbbVie
VUITY (pilocarpine HCI ophthalmic solution) 1.25%, developed by Allergan, is a novel treatment for presbyopia approved by the US FDA In October 2021. This prescription eye drop works by contracting the pupil to enhance near and intermediate vision without significantly affecting distance vision. By leveraging the miotic properties of pilocarpine, VUITY improves focus for close-up tasks, offering a non-invasive alternative to reading glasses. Its approval marks a significant advancement in presbyopia management, providing patients with a convenient and effective option to alleviate the condition’s symptoms.
- QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%: Orasis Pharmaceuticals
QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, developed by Orasis Pharmaceuticals, is a novel treatment for presbyopia that was approved by the US FDA in October 2023. This formulation aims to improve near vision by using pilocarpine, a cholinergic muscarinic agonist, to enhance the eye’s accommodative ability. The market launch of QLOSI is anticipated in the second half of 2024, offering a new option for patients seeking a non-surgical approach to managing age-related vision decline.
Presbyopia Emerging Drugs
- Brimochol PF (VT-1011): Visus Therapeutics
Brimochol PF (VT-1011), which is being developed by Visus Therapeutics, is a novel treatment for presbyopia. This investigational eye drop formulation combines brimonidine, a selective alpha-2 adrenergic agonist, with carbachol, a muscarinic agonist, to improve near vision by enhancing the eye’s accommodative response. Currently, Brimochol PF is in the late stages of clinical development, having completed Phase III trials, which have demonstrated its efficacy and safety profile. The product is expected to have its New Drug Application (NDA) filed in the second half of 2024, aiming to offer a new therapeutic option for managing presbyopia.
- LNZ100 – 1.75% Aceclidine: LENZ Therapeutics, Inc.
LNZ100 – 1.75% Aceclidine, developed by LENZ Therapeutics, Inc., is a promising treatment for presbyopia. This formulation utilizes Aceclidine, a parasympathomimetic agent, to improve near vision by enhancing the eye’s accommodative response. Currently, LNZ100 is in advanced clinical stages, with the company planning to submit an NDA to the FDA in mid-2024. The projected market launch for LNZ100 is targeted for the second half of 2025, positioning it as a key therapeutic option for managing presbyopia.
Get In-Depth Knowledge on Presbyopia Market Trends and Forecasts with DelveInsight @ Presbyopia Treatment Market
Presbyopia Market Outlook
The market for presbyopia treatments encompasses a diverse range of options, catering to various patient preferences and needs. Non-invasive solutions, such as reading glasses, bifocals, and progressive lenses, offer clear vision at different distances, making them popular among those seeking convenience. Contact lenses, including multifocal and monovision types, further enhance flexibility and field of vision compared to traditional eyewear. Pharmacological treatments have emerged as promising options. Eye drops like pilocarpine hydrochloride temporarily enhance near vision by constricting the pupil, thus improving depth of field. Among the notable advancements, FDA-approved treatments such as VUITY and QLOSI represent significant progress.
Scope of the Presbyopia Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Presbyopia Companies- AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire Pharma, and others.
- Presbyopia Therapies- Pilocarpine, Phentolamine Opthalmic Solution 0.75%, UNR844-Cl, CSF-1, and others.
- Presbyopia Therapeutic Assessment: Presbyopia Current marketed and Presbyopia Emerging Therapies
- Presbyopia Market Dynamics: Presbyopia Market drivers and Presbyopia Market Barriers
Gain a strategic edge in the Presbyopia Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Presbyopia Market Forecast. Click here to lead in advancements @ Presbyopia Clinical Trials Assessment
Table of Content
1. Key Insights
2. Presbyopia Report Introduction
3. Presbyopia Market Overview at a Glance
4. Presbyopia Market: Future Perspective
5. Executive Summary
6. Key Events
7. Presbyopia Disease Background and Overview
8. Presbyopia Epidemiology and Patient Population
9. Patient Journey
10. Presbyopia Marketed Drugs
11. Key Presbyopia Emerging Therapies
12. Presbyopia: Seven Major Market Analysis
13. Presbyopia KOL Views
14. Presbyopia SWOT Analysis
15. Presbyopia Unmet Needs
16. Presbyopia Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage